On July 28, 2026, ORIC Pharmaceuticals' Board approved the Amended and Restated 2022 Inducement Equity Incentive Plan, increasing reserved shares by 1,100,000 to a total of 3,350,000. This action was taken without stockholder approval under Nasdaq Listing Rules to facilitate equity awards for new hires or merger-related acquisitions. The company operates in the biopharmaceutical industry.
